BALTIMORE ( Stockpickr) — Which stocks should I buy? It’s the eternal question that most investors spend most of their time wondering. But is it the wrong question?
Must Read: Warren Buffett’s Top 10 Dividend Stocks
More so than any other year since 2008’s market crash, 2014 has been a year for stock pickers. That’s because, as the end of the calendar year creeps closer, one in three S&P 500 components is actually down since January. And considering the fact that the big index is up more than 10% year-to-date, those underperformers are missing the mark by a big margin. In a big way, knowing which stocks not to buy has almost been more important for your ability to book gains in 2014 than knowing which ones you should.
That’s why we’re taking a closer technical look at five “toxic stocks” to sell this week.
Just to be clear, the companies I’m talking about today aren’t exactly junk. By that, I mean they’re not next up in line at bankruptcy court. But that’s frankly irrelevant; from a technical analysis standpoint, sellers are shoving around these toxic stocks right now. For that reason, fundamental investors need to decide how long they’re willing to take the pain if they want to hold onto these firms in the weeks and months ahead. And for investors looking to buy one of these positions, it makes sense to wait for more favorable technical conditions (and a lower share price) before piling in.
best stocks to own: Citi Trends, Inc.(CTRN)
- [By Lisa Levin]
Citi Trends, Inc. (NASDAQ: CTRN) shares shot up 16 percent to $19.38 after the company posted upbeat quarterly earnings.
Shares of Internap Corp (NASDAQ: INAP) got a boost, shooting up 13 percent to $2.97 on strong quarterly results. Stifel Nicolaus upgraded Internap from Hold to Buy and raised the price target from $2.00 to $5.50.
best stocks to own: Mastercard Incorporated(MA)
- [By Matthew Cochrane]
Mastercard Inc’s (NYSE:MA) shares are now near all-time highs, as its consistent and steady growth has driven the stock to amazing heights since its IPO a little more than a decade ago. Since going public, Mastercard’s stock price has skyrocketed more than 2,400%! More recent investors have nothing to complain about either as shares have increased nearly 13% year-to-date. Its recent quarter is just another impressive benchmark in its life as a public company.
- [By Brian Feroldi, Dan Caplinger, Rich Duprey, Jason Hall, and Jordan Wathen]
In order to point you in the right direction, we asked a team of Fools to highlight a dividend stock that they feel is a great stock for a beginner. Read on to see why they picked AT&T (NYSE:T),Apple (NASDAQ:AAPL),Anheuser-Busch InBev(NYSE:BUD), Mastercard(NYSE:MA), andJPMorgan Chase(NYSE:JPM).
- [By Dan Caplinger]
Visa Inc. (NYSE:V) and MasterCard (NYSE:MA) aren’t the only two players in the credit card and electronic payments space, but they are the biggest and best-known. Both Visa and MasterCard have extended their reach across the globe, and both have high expectations in their trajectories for future growth. Yet after a big push in the stock market that has sent both of these financial stocks to all-time highs, investors need to know which of the two leaders in the card industry is more deserving of their attention. Let’s take a closer look at Visa and MasterCard, comparing them using several different metrics to see which company’s shares are the better buy.
- [By WWW.KIPLINGER.COM]
Visas not alone when it comes to being a dividend miser. Rival MasterCard Inc (MA) is every bit as bad.
MasterCards dividend payout ratio is an extremely low 21%, and its dividend yield is a pitiful 0.8%. I suppose that might be competitive with a savings account these days. But its less than half the dividend yield of the S&P 500, and theres just no excuse for that.
- [By Mitchell Clark]
This is a stock to own for the long term. It has an excellent long-term track record. Management just announced another dividend increase and more share repurchases.
Earnings growth in 2016 is expected to accelerate over the performance in 2015. The big credit card brands are institutional favorites.
MasterCard Incorporated’s (NYSE:MA) sales and earnings growth have been quite consistent over the years.
- [By David Zeiler]
Ethereum has plenty of real-world catalysts driving it already:
It’s become the foundation of the booming ICO phenomenon, through which cryptocurrency-based startups have raised millions of dollars in a matter of minutes. Most new tokens are either based on Ethereum and/or require users to buy the cryptocurrency with Ethereum. It’s Turing complete, which means the Ethereum network can function as a giant, global computer. That’s what makes Ethereum an ideal platform for applications like smart contracts. And it’s enabled the creation of a new kind of app, “Dapps,” or distributed applications that run on the network. Businesses are adopting it. The 150-plus companies in the Enterprise Ethereum Alliance include some of the world’s biggest and most prestigious corporations, such as JPMorgan Chase & Co. (NYSE:JPM), Microsoft Corp. (Nasdaq: MSFT), Mastercard Inc. (NYSE: MA), and Deloitte.
Related: What’s the Best Cryptocurrency to Invest in Today?
best stocks to own: Great Plains Energy Inc(GXP)
- [By Dan Caplinger]
Westar Energy stock declined 8% after regulators at the Kansas Corporation Commissions blocked the sale of Westar to Great Plains Energy (NYSE:GXP). The $12.2 billion merger would have joined utilities in Kansas and Missouri. Great Plains had argued that the combination would produce nearly $2 billion in efficiency gains in the next 10 years, but regulators instead sided with those who had argued that the deal was too rich and would have required rate increases sooner rather than later. Great Plains stock was hardly affected at all by the decision, leading many to conclude that Westar had a lot more to lose from the deal falling through then Great Plains had to gain from a successful merger.
best stocks to own: Wayfair Inc.(W)
- [By Lisa Levin]
Wayfair Inc (NYSE: W) shares were also up, gaining 25 percent to $63.71 after first-quarter earnings boasted a 2.7-percent sales beat and 46-percent year-over-year increase in active customers.
- [By Peter Graham]
The Q4 2016 earnings report formid cap online home furnishings and d茅cor stockWayfair Inc (NYSE: W) is scheduled for before the market opens onThursday (February 23rd) as shares still have elevated short interest of 34.99% according to Highshortinterest.com. Last time around, shares dropped as much as 13%after the Company reported third quarter revenues and net losses that largely met expectations while projecting aslight decrease in revenue growth for the coming quarter.
- [By Peter Graham]
Mid cap online home furnishings and d茅cor stockWayfair Inc (NYSE: W) reported Q1 earnings before the market opened with the Company being thetenth most shorted stock on the NYSE with short interest of 39.22% according to Highshortinterest.com. In the summer of 2008,the shorts and shareholder rights law firms went after Wayfair Inc after short seller Citron Research issued a report (entitled: Wayfair is the Most Mispriced Stock Citron Research has Seen in Years: Fair Value Under $10) calling the company Overstock.com, Inc (NASDAQ: OSTK):
best stocks to own: Ionis Pharmaceuticals, Inc.(IONS)
- [By WWW.THESTREET.COM]
Coming up in this episode of Mad Money: Cramer interviews Dr. Stanley Crooke, CEO of Ionis Pharmaceuticals (IONS) . And, here’s Cramer’s read on Trump’s view of China. Plus, don’t miss the Lightning Round. Which stocks in Cramer bullish on?
- [By Cory Renauer]
Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.
- [By Brian Orelli]
Ionis Pharmaceuticals (NASDAQ:IONS) gave investors an update on its pipeline today with a slide deck that contained a whopping 65 entries. The whole presentation is worth a listen, but here are the five slides investors absolutely must see.
- [By Keith Speights]
Research and development is the lifeblood of biotech companies. The potential for new drugs also serves as a primary factor driving biotech stocks higher and higher. That’s been the case for Celgene (NASDAQ:CELG), Ionis Pharmaceuticals (NASDAQ:IONS), and Ligand Pharmaceuticals (NASDAQ:LGND).
- [By Elizabeth Balboa]
Here is a preview of the offerings set between June 27 and June 30.
11 IPOs This Week Avenue Therapeutics, Inc. (ATXI) will issue 5 million shares between $5 and $7 Tuesday on the Nasdaq. A Fortress Biotech Inc (NASDAQ: FBIO) subsidiary, the pharmaceutical acquires, develops and commercializes products for in-hospital use, such as its post-operative palliative. Esquire Financial Holdings, Inc. (ESQ) will issue more than 2.36 shares between $14 and $16 Tuesday on the Nasdaq. The business-focused commercial bank has two locations in New York and Florida. Mersana Therapeutics, Inc. (MRSN) will issue 5 million shares between $14 and $16 Wednesday on the Nasdaq. The clinical-stage pharmaceutical specializes in immunoconjugate therapies targeting diverse forms of cancer. TPG Pace Holdings Corp. (TPGHU) will issue 40 million shares at $10 Wednesday on the New York Stock Exchange. Formed by TPG, the firm acquires relevant businesses and stocks across industries, from health care and digital media to real estate and energy. Aileron Therapeutics Inc (ALRN) will issue 3.75 million shares between $15 and $17 Thursday on the Nasdaq. The biopharmaceutical firm targets suppressor proteins to halt tumor progression. Blue Apron Holdings, Inc. (APRN) will issue 30 million shares between $15 and $17 Thursday on the NYSE. The meal-kit service delivers pre-portioned ingredients directly to the consumer. Byline Bancorp, Inc. (BY) will issue 5.7 million shares between $19 and $21 Thursday on the NYSE. The century-old commercial bank has more than 50 branches in the Chicago and Milwaukee areas with offices nationwide. Dova Pharmaceuticals, Inc.(DOVA) will issue more than 4.06 million shares between $15 and $17 Thursday on the Nasdaq. As a clinical-stage company, Dova acquires, develops and commercializes drug candidates for rare diseases. Tintri, Inc. (TNTR) will issue 8.7 million shares between $10.50 and $12.50 Thursday on the Nasdaq. With cloud management software, all-flash stor
best stocks to own: Brooks Automation Inc.(BRKS)
- [By Lisa Levin]
In trading on Friday, technology shares fell 3.59 percent. Meanwhile, top losers in the sector included Ultra Clean Holdings Inc (NASDAQ: UCTT), down 5 percent, and Brooks Automation, Inc (NASDAQ: BRKS), down 10 percent.
- [By Lisa Levin]
Technology sector was the top gainer in the US market on Monday. Top gainers in the sector included Aviat Networks Inc (NASDAQ: AVNW), Cohu, Inc. (NASDAQ: COHU), and Brooks Automation, Inc (NASDAQ: BRKS).